Data supports use of Channel Medsystems Cerene cryotherapy

Channel Medsystems announced today that long-term clinical outcomes support its Cerene cryotherapy for treating heavy menstrual bleeding (HMB).

Long-term outcomes from the Clarity clinical study evaluating the safety and effectiveness of Cerene cryotherapy were published in the¬†International Journal of Women’s Health.

Emeryville, California-based Channel Medsystems designed Cerene as a proprietary, hand-held technology for delivering cryotherapy to the lining of the uterus, freezing the tissue and significantly reducing future menstrual bleeding. The company received FDA approval for the platform in 2020.

The in-office endometrial cryoablation treatment safely and effectively reduces heavy menstrual bleeding while naturally minimizing pain without requiring general anesthesia, the company said in a news release.

In the study, Cerene is presented as a well-tolerated endometrial ablation that provides a significant reduction in HMB symptoms an…

Read more
  • 0

Channel Medsystems makes three appointments to management team including new CFO

Channel Medsystems announced today that it appointed three new members to its executive team, including a new chief financial officer.

Berkeley, California-based Channel Medsystems named Ian Vawter as VP and CFO, Rebecca Furlong as VP and president of U.S. sales and Nital Patel Bryant as senior director of marketing.

Channel Medsystems develops the Cerene cryotherapy device for treating menstrual bleeding. The next-generation platform received FDA approval in July 2020 and the company said in a news release that the appointments follow a successful early commercial launch in September 2021.

Vawter joins with 25 years of financial experience, Channel Medsystems said, having most recently served as VP and CFO at Tepha, which was acquired by BD.

Furlong carries nearly three decades of experience in medical devices and pharmaceuticals, the company said, including work in women’s health. She most recently served as area VP of sales at Takeda.

Read more
  • 0

FDA approves Channel Medsystems’ cryotherapy device

Channel Medsystems announced today that it received FDA approval for its next-generation Cerene cryotherapy device for treating menstrual bleeding.

Cerene initially received FDA premarket approval in March 2019 as a device with proprietary, hand-held technology for delivering cryotherapy to the lining of the uterus, freezing the tissue and significantly reducing future menstrual bleeding.

The device does not require gynecologists to invest in capital equipment and does not require the use of general anesthesia, enabling convenient and comfortable procedures to be performed in a gynecologist’s office.

Emeryville, Calif.-based Channel Medsystems’ newest version of the device delivers the 2.5-minute cryotherapy treatment with improvements to the manufacturing process ahead of scale-ups intended to meet the anticipated demand for office-based therapy, according to a news release.

“We are extremely pleased to announce the latest miles…

Read more
  • 0